6- amino- N- (3- (4- (4- morpholinyl)pyrido(3',2'- 4,5)furo(3,2- d)pyrimidin- 2- yl)phenyl)- 3- pyridinecarboxamide

an antiviral agent; structure in first source

Also Known As:

YM 201636; YM-201636; YM201636

Networked: 5 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 140
- Amines: 4925
  - Aminopyridines: 78
    - 6-amino-N-(3-(4-(4-morpholinyl)pyrido(3',2'-4,5)furo(3,2-d)pyrimidin-2-yl)phenyl)-3-pyridinecarboxamide: 5
Heterocyclic Compounds: 207
- 1-Ring Heterocyclic Compounds
  - Pyridines: 91
    - Aminopyridines: 78
      - 6-amino-N-(3-(4-(4-morpholinyl)pyrido(3',2'-4,5)furo(3,2-d)pyrimidin-2-yl)phenyl)-3-pyridinecarboxamide: 5
- Fused-Ring Heterocyclic Compounds
  - 3-Ring Heterocyclic Compounds
    - 6-amino-N-(3-(4-(4-morpholinyl)pyrido(3',2'-4,5)furo(3,2-d)pyrimidin-2-yl)phenyl)-3-pyridinecarboxamide: 5

Experts

1.	Baker, Jonathan: 1 article (12/2023)
2.	Daly, Leah: 1 article (12/2023)
3.	Ito, Kazuhiro: 1 article (12/2023)
4.	Knowles, Ian: 1 article (12/2023)
5.	Ombredane, Hugo: 1 article (12/2023)
6.	Rapeport, Garth: 1 article (12/2023)
7.	Guo, Jun: 1 article (01/2023)
8.	Li, Yongkui: 1 article (01/2023)
9.	Liang, Yicong: 1 article (01/2023)
10.	Luo, Zhen: 1 article (01/2023)

Related Diseases

1.	Vesicular Stomatitis 01/01/2023 - "Further studies found that YM201636 broadly represses the replication of other RNA viruses, including coxsackievirus B3 (CVB3), poliovirus 1 (PV1), echovirus 11 (E11), Zika virus (ZIKV), and vesicular stomatitis virus (VSV), rather than DNA viruses, including adenovirus 3 (ADV3) and hepatitis B virus (HBV). "
2.	Liver Neoplasms (Liver Cancer) 03/01/2019 - "The aim of the present study was to investigate whether the phosphatidylinositol‑3‑phosphate 5‑kinase (PIKfyve) inhibitor, YM201636, exerts anti‑proliferative effects on liver cancer. " 03/01/2019 - "The autophagy inhibitor 3‑methyladenine attenuated the inhibitory effects of YM201636 on liver cancer cell proliferation. " 03/01/2019 - "Inhibition of PIKfyve using YM201636 suppresses the growth of liver cancer via the induction of autophagy."
3.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/2021 - "The aim of the present study was to investigate the effects of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) inhibitor, YM201636, on nonsmall cell lung cancer (NSCLC) cells growth, tumorigenicity, and claudin (CLDN) expressions. "
4.	Neoplasms (Cancer) 01/01/2021 - "Our results revealed that YM201636 inhibited the proliferation and malignancy potential of Calu-1, H1299, and HCC827 cells in a dose-dependent manner. " 03/01/2019 - "Collectively, these results suggested that the PIKfyve inhibitor YM201636 may inhibit tumor growth by promoting EGFR expression. " 03/01/2019 - "Further in vivo analysis revealed that YM201636 (2 mg/kg) inhibited tumor growth without notable systemic toxicity. " 01/01/2021 - "The effects of PIKfyve inhibitor YM201636 on claudins and malignancy potential of nonsmall cell cancer cells."
5.	Multiple Myeloma 01/01/2020 - "The broad anti-multiple myeloma activity of PIKfyve inhibitors was further demonstrated in confirmatory screens and showed the superior potency of APY0201 when compared to the PIKfyve inhibitors YM201636 and apilimod, with a mid-point half maximal effective concentration (EC50) at nanomolar concentrations in, respectively, 65%, 40%, and 5% of the tested cell lines. "

Related Drugs and Biologics

1.	Claudins
2.	apilimod
3.	1-Phosphatidylinositol 4-Kinase (1 Phosphatidylinositol 4 Kinase)
4.	Phosphotransferases (Kinase)
5.	APY0201